FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4293498894> ?p ?o ?g. }

• W4293498894 endingPage "75" @default.
• W4293498894 startingPage "69" @default.
• W4293498894 abstract "Pathological digital rectal examination (DRE) is suggestive of prostate cancer but has low sensitivity and specificity. DRE is incorporated in many clinical risk calculators, but there is less evidence on how DRE performs in the setting of blood biomarkers and polygenic risk prediction models other than prostate-specific antigen (PSA) associated with prostate cancer. The Stockholm3 test combines a blood test and clinical variables including DRE.To assess the predictive performance of DRE for finding clinically significant prostate cancer in systematic biopsy and evaluate its added value to the multivariable diagnostic test Stockholm3.This population-based study in the screening by invitation setting included 5543 men aged 50-69 yr with PSA ≥3 ng/ml who were referred for systematic prostate biopsy between 2012 and 2015. The STHLM3 study is registered with ISRCTN.com as ISRCTN84445406.Predictive performance was assessed via estimates of sensitivity and specificity and in logistic regression. Clinically significant cancer was defined as International Society of Urological Pathology grade group ≥2 (GG ≥2) cancer on systematic biopsy.We found that 11% of men with PSA ≥3 ng/ml had a suspicious DRE. A suspicious DRE was associated with a 3.16-fold higher risk (95% confidence interval [CI] 2.83-3.52) of GG ≥2 cancer and greater length of cancer on biopsy. The risk of nonsignificant cancer was similar regardless of the DRE finding. The risk of GG ≥2 cancer was 46.2% (95% CI 42.2-50.3%) for men with a suspicious DRE versus 14.6% (95% CI 13.7-15.7%) for men with a negative DRE. The elevated risk of GG ≥2 cancer persisted after adjusting for the other Stockholm3 test parameters (odds ratio 2.88, 95% CI 2.32-3.57). For detection of GG ≥2 cancer among men with PSA ≥3 ng/ml, DRE had sensitivity of 27.8% (95% CI 25.1-30.7%) and specificity of 92.8% (95% CI 92.1-93.6%).In this screening-by-invitation setting we found that for men with PSA ≥3 ng/ml, a suspicious DRE indicates more than threefold higher risk of harboring significant prostate cancer. DRE as a variable adds significant precision to the Stockholm3 prediction model. Men with a suspicious DRE should be referred for further diagnostic workup, including biopsy.We investigated the ability of digital rectal examination to predict if a patient has clinically significant prostate cancer. We found that digital rectal examination provides valuable information and can help doctors in making an informed decision on whether to recommend prostate biopsy." @default.
• W4293498894 created "2022-08-29" @default.
• W4293498894 creator A5005980125 @default.
• W4293498894 creator A5021982213 @default.
• W4293498894 creator A5024500466 @default.
• W4293498894 creator A5041203778 @default.
• W4293498894 creator A5048846522 @default.
• W4293498894 creator A5068804634 @default.
• W4293498894 creator A5073429275 @default.
• W4293498894 creator A5080563805 @default.
• W4293498894 date "2022-10-01" @default.
• W4293498894 modified "2023-10-11" @default.
• W4293498894 title "Digital Rectal Examination in Stockholm3 Biomarker-based Prostate Cancer Screening" @default.
• W4293498894 cites W1981042128 @default.
• W4293498894 cites W2019720500 @default.
• W4293498894 cites W2023232494 @default.
• W4293498894 cites W2024053741 @default.
• W4293498894 cites W2026019149 @default.
• W4293498894 cites W2026838241 @default.
• W4293498894 cites W2039135639 @default.
• W4293498894 cites W2063969905 @default.
• W4293498894 cites W2165416035 @default.
• W4293498894 cites W2191311785 @default.
• W4293498894 cites W2302166841 @default.
• W4293498894 cites W2328176404 @default.
• W4293498894 cites W2418248420 @default.
• W4293498894 cites W2577453388 @default.
• W4293498894 cites W2765503564 @default.
• W4293498894 cites W2804413706 @default.
• W4293498894 cites W2904914487 @default.
• W4293498894 cites W2921681381 @default.
• W4293498894 cites W3097158220 @default.
• W4293498894 cites W3119591473 @default.
• W4293498894 cites W4242570784 @default.
• W4293498894 doi "https://doi.org/10.1016/j.euros.2022.08.006" @default.
• W4293498894 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36185581" @default.
• W4293498894 hasPublicationYear "2022" @default.
• W4293498894 type Work @default.
• W4293498894 citedByCount "3" @default.
• W4293498894 countsByYear W42934988942023 @default.
• W4293498894 crossrefType "journal-article" @default.
• W4293498894 hasAuthorship W4293498894A5005980125 @default.
• W4293498894 hasAuthorship W4293498894A5021982213 @default.
• W4293498894 hasAuthorship W4293498894A5024500466 @default.
• W4293498894 hasAuthorship W4293498894A5041203778 @default.
• W4293498894 hasAuthorship W4293498894A5048846522 @default.
• W4293498894 hasAuthorship W4293498894A5068804634 @default.
• W4293498894 hasAuthorship W4293498894A5073429275 @default.
• W4293498894 hasAuthorship W4293498894A5080563805 @default.
• W4293498894 hasBestOaLocation W42934988941 @default.
• W4293498894 hasConcept C121608353 @default.
• W4293498894 hasConcept C126322002 @default.
• W4293498894 hasConcept C143998085 @default.
• W4293498894 hasConcept C151956035 @default.
• W4293498894 hasConcept C185592680 @default.
• W4293498894 hasConcept C2775934546 @default.
• W4293498894 hasConcept C2775941076 @default.
• W4293498894 hasConcept C2776235491 @default.
• W4293498894 hasConcept C2779599708 @default.
• W4293498894 hasConcept C2780101318 @default.
• W4293498894 hasConcept C2780192828 @default.
• W4293498894 hasConcept C2781197716 @default.
• W4293498894 hasConcept C2781217009 @default.
• W4293498894 hasConcept C2781406297 @default.
• W4293498894 hasConcept C2908647359 @default.
• W4293498894 hasConcept C29456083 @default.
• W4293498894 hasConcept C44249647 @default.
• W4293498894 hasConcept C55493867 @default.
• W4293498894 hasConcept C71924100 @default.
• W4293498894 hasConcept C99454951 @default.
• W4293498894 hasConceptScore W4293498894C121608353 @default.
• W4293498894 hasConceptScore W4293498894C126322002 @default.
• W4293498894 hasConceptScore W4293498894C143998085 @default.
• W4293498894 hasConceptScore W4293498894C151956035 @default.
• W4293498894 hasConceptScore W4293498894C185592680 @default.
• W4293498894 hasConceptScore W4293498894C2775934546 @default.
• W4293498894 hasConceptScore W4293498894C2775941076 @default.
• W4293498894 hasConceptScore W4293498894C2776235491 @default.
• W4293498894 hasConceptScore W4293498894C2779599708 @default.
• W4293498894 hasConceptScore W4293498894C2780101318 @default.
• W4293498894 hasConceptScore W4293498894C2780192828 @default.
• W4293498894 hasConceptScore W4293498894C2781197716 @default.
• W4293498894 hasConceptScore W4293498894C2781217009 @default.
• W4293498894 hasConceptScore W4293498894C2781406297 @default.
• W4293498894 hasConceptScore W4293498894C2908647359 @default.
• W4293498894 hasConceptScore W4293498894C29456083 @default.
• W4293498894 hasConceptScore W4293498894C44249647 @default.
• W4293498894 hasConceptScore W4293498894C55493867 @default.
• W4293498894 hasConceptScore W4293498894C71924100 @default.
• W4293498894 hasConceptScore W4293498894C99454951 @default.
• W4293498894 hasLocation W42934988941 @default.
• W4293498894 hasLocation W42934988942 @default.
• W4293498894 hasLocation W42934988943 @default.
• W4293498894 hasOpenAccess W4293498894 @default.
• W4293498894 hasPrimaryLocation W42934988941 @default.
• W4293498894 hasRelatedWork W1541131697 @default.
• W4293498894 hasRelatedWork W2026584834 @default.
• W4293498894 hasRelatedWork W2064191137 @default.

• next